Informations générales (source: ClinicalTrials.gov)
Serum Neurofilament-light Chain and Glial Fibrillary Acidic Proten (GFAP) Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis (NeurofilMS)
Observational
Centre Hospitalier Universitaire de Nīmes (Voir sur ClinicalTrials)
mai 2019
juin 2028
29 juin 2024
The investigators hypothesize that serum neurofilament-light chain (NfL) levels can
provide information about the level of activity and progression of Multiple Sclerosis at
different stages and landmarks of the disease.
In addition, Glial Fibrillary Acidic Protein (GFAP) has also been identified as another
serum biomarker of disability in MS.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| HOPITAL FONDATION A. DE ROTHSCHILD | Caroline BENSA | 21/06/2024 13:32:51 | Contacter | ||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| AP-HP - Hôpital La Pitié-Salpêtrière | Catherine LUBETZKI | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital Saint Antoine | Bruno Prénom Bruno Bruno STANKOFF | Contact (sur clinicalTrials) | |||
| CHI POISSY ST-GERMAIN | Olivier HEINZLEF | Contact (sur clinicalTrials) | |||
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CHU de Besancon - Besançon - France | Eric BERGER | Contact (sur clinicalTrials) | |||
| CHU de Clermont Ferrand - Clermont-Ferrand - France | Pierre CLAVELOU | Contact (sur clinicalTrials) | |||
| CHU de Limoges - Limoges - France | Laurent MAGY | Contact (sur clinicalTrials) | |||
| CHU de Nancy - Nancy - France | Marc DEBOUVERIE | Contact (sur clinicalTrials) | |||
| CHU de Nice - Nice - France | Christine Lebrun-Frenay | Contact (sur clinicalTrials) | |||
| CHU de Potiers - Potiers - France | Jean Philippe NEAU | Contact (sur clinicalTrials) | |||
| CHU de Rennes - Rennes - France | Emanuelle LE PAGE | Contact (sur clinicalTrials) | |||
| CHU de Saint Etienne - Saint-Étienne - France | Jean Philippe CAMDESSANCHE | Contact (sur clinicalTrials) | |||
| CHU de Strasbourg - Strasbourg - France | Jérôme DE SEZE | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CHU d'Amiens - Amiens - France | Abdullatif AL KHEDR | Contact (sur clinicalTrials) | |||
| CHU de Bordeaux - Bordeaux - France | Bruno BROCHET | Contact (sur clinicalTrials) | |||
| CHU de Caen - Caen - France | Nathalie DERACHE | Contact (sur clinicalTrials) | |||
| CHU de Dijon - Dijon - France | Thibault MOREAU | Contact (sur clinicalTrials) | |||
| CHU de Grenoble - Grenoble - France | Olivier CASEZ | Contact (sur clinicalTrials) | |||
| CHU de Lille - Lille - France | Hélène ZEPHIR | Contact (sur clinicalTrials) | |||
| CHU de Lyon - Lyon - France | Sandra VUKUSIC | Contact (sur clinicalTrials) | |||
| CHU de Montpellier - Montpellier - France | Pierre LABAUGE | Contact (sur clinicalTrials) | |||
| CHU de Nimes - 30029 - Nîmes - France | Anissa Megzari | Contact (sur clinicalTrials) | |||
| CHU de Rouen - Rouen - France | Bertrand BOURRE | Contact (sur clinicalTrials) | |||
| CHU de Toulouse - Toulouse - France | Damien BIOTTI | Contact (sur clinicalTrials) | |||
| CHU de Tours - Tours - France | Anne-Marie GUENNOC | Contact (sur clinicalTrials) | |||
| Hopital Henri Mondor - Créteil - France | Alain CREANGE | Contact (sur clinicalTrials) | |||
| Hopital Timone - Marseille - France | Jean PELLETIER | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- The patient has been correctly informed.
- The patient must have given their informed and signed consent.
- The patient must be insured or beneficiary of a health insurance plan.
- The patient is at least (≥)15 years old.
- The patient has MS according to diagnosis criteria (Thompson et al. 2017) and:
- Participates to the OFSEP-HD cohort (ancillary study);
- Has a Expanded Disability Status Scale score comprised between 0 - 7.0;
- With or without Disease Modifying Drug;
- For Work Package 3: patients enrolled in any OFSEP-HD centre that meet landmark
criteria for an active MS (relapse, or Expanded Disability Status Scale
progression, or active MRI) during follow-up;
- For Work Package 4: patients with a stable disease enrolled in OFSEP-HD study
in Nîmes or Nantes University Hospitals.
- The patient has been correctly informed.
- The patient must have given their informed and signed consent.
- The patient must be insured or beneficiary of a health insurance plan.
- The patient is at least (≥)15 years old.
- The patient has MS according to diagnosis criteria (Thompson et al. 2017) and:
- Participates to the OFSEP-HD cohort (ancillary study);
- Has a Expanded Disability Status Scale score comprised between 0 - 7.0;
- With or without Disease Modifying Drug;
- For Work Package 3: patients enrolled in any OFSEP-HD centre that meet landmark
criteria for an active MS (relapse, or Expanded Disability Status Scale
progression, or active MRI) during follow-up;
- For Work Package 4: patients with a stable disease enrolled in OFSEP-HD study
in Nîmes or Nantes University Hospitals.
- Within the past three months, the patient has participated in another interventional
study that may interfere with the results or conclusions of this study.
- The patient is in an exclusion period determined by a previous study.
- The patient is under judicial protection.
- The patient refuses to sign the consent.
- It is impossible to correctly inform the patient (inability to understand the study,
language problem).
- The patient is pregnant or breast-feeding.
- The patient is under 15 years old.
- Inability to answer questionnaires.
- Clinically isolated syndrome (CIS) that does not meet the criteria of MS.
- Radiologically isolated syndrome (RIS).
- Patient with Neuromyelitis optica spectrum disorder.